title: A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.
authors.forename: Philip
authors.initials: P
authors.lastname: Home
authors.forename: Adrian
authors.initials: A
authors.lastname: Bagust
authors.forename: Matthew
authors.initials: M
authors.lastname: Taylor
authors.forename: Philip
authors.initials: P
authors.lastname: Ambery
authors.forename: Samara
authors.initials: S
authors.lastname: Mendes da Costa
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000191:economics; D017048:Health Care Costs; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics* / Q000627:therapeutic use; D018803:Models, Economic; D000077205:Pioglitazone; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000191:economics* / Q000627:therapeutic use